Business
BCX: Advanced cell therapy pipeline, secured funding, and strengthened readiness for commercialization
BCX: Advanced cell therapy pipeline, secured funding, and strengthened readiness for commercialization
About this update from Bioceltix Sa
Advanced three cell therapy products for veterinary use, secured GMP certification, and raised PLN 53 million to fund a new manufacturing facility, while maintaining a strong cash position and progressing toward commercialization despite ongoing net losses and no product revenue.Original document: This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.